Following up the presentation of our project with a pharma company in the Netherlands on How Pharma can enhance its impact and reduce costs of marketing, we present our chalkboard sketch to construe a new commercial model for a pharmaceutical market approach: an approach that would guide the decision makers in the company to construe the right set of activities to focus on accounts with the best chances of success, engage with its decision makers on drug prescription effectively and provide added value to their medicines so as to help care providers to help their patients better.
Having witnessed the Dutch Health Care Reform (see Wikipedia), it is inspiring to review it to evaluate what processes and forces have initiated the development and formed its course.
Based upon our studies, we construed this presentation
The best digital health app is conversation
Although our attention may be distracted from time to time by a health-related smartphone or tablet app, a health tracking device, a quantified self peripheral, or some another piece of shiny, soon-to-be-outmoded future junk, I hope it is becoming obvious by now that the best digital health app currently available is conversation.
So indeed, a change in attitude to listen rather than to speak may help us getting on!
In health care, patients are often left alone with their therapies. Currently, we see service and marketing in health care efforts using the internet to fill the patientsâ€™ most obvious needs. Information services, indication backgrounds, drug information, patient stories, communities around peers, compliance guidelines are all services brought to the patient on a one-to-one basis.
From a health care perspective, these efforts are innovative, but do not present a structural attempt to systematically arrange all or several of the elements that caring for oneâ€™s health condition may include.
Setting up and delivering an integrated context for servicing patientsâ€™ needs and demands will be more beneficial to patients in coping with their condition, as well as to the stakeholders relating to them in pursuing their health care business.
Originally posted on “Value innovation in medical and life sciences” ; July 30th, 2010
What you may like to prevent just by using social media in health care.
Hereâ€™s a Dutch father complaining about the reimbursement of a continuous glucose monitoring system in a national newspaper. For the control of his daughterâ€™s diabetes, who has also a Down syndrome, he is only reimbursed for a normal glucose meter, not the wished for continuous glucose monitoring system.
The father states that the health care insurance company informed him, unsolicited: â€œWe want you to know that continuous monitoring can not be reimbursed.â€ Thatâ€™s what it was. He is amazed that the Down condition of his daughter is not a concern to them whatsoever? Shouldnâ€™t it have been taken into account?
Origonally posted on “Value innovation in medical and life sciences” ; September 27th, 2009
Recently, I focused on the developments in the technology of implantable pacemakers and defibrillators (http://bit.ly/8VRkZP ) . I did so in the course of a consult to one of the affiliates of the cardiac devices industry in the Netherlands. I was asked to think along in the further development of cardiological care around these devices. The intention was to develop what was called as remote monitoring of cardiac devices into a design of an adequate model for integrated care in cardiology.
In reflection on the information I gathered, I distinguished two realms of development, each with their own dimensions. To implement the technological features to the conduct of care and benefit from its outcomes and processes, and specifically for the benefits of the patient, both realms of developments need to be actively attended to…
Originally posted on “Value innovation in medical and life sciences”; August 21th, 2009